Meta-analysis of statins for treatment of vascular cognitive impairment
10.3969/j.issn.2095-4344.2013.50.023
- VernacularTitle:他汀类药物治疗血管性认知障碍的Meta分析
- Author:
Sen LI
;
Wanpeng XU
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2013;(50):8769-8774
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:No international reports had shown that statins were effective for the treatment of vascular cognitive impairment. However, Chinese studies concerning effects of statins on vascular dementia had a smal sample size, so no definite conclusion was obtained.
OBJECTIVE:To perform a meta-analysis on effects of statins on vascular cognitive impairment, the methods recommended by the Cochrane Col aboration were used.
METHODS:The databases such as China National Knowledge Internet, Wanfang, VIP, Chinese Biological and Medical Database and PubMed Medline were searched by computer and manual y for randomized control ed trials about the effect of statins on vascular cognitive impairment. Retrieval time was from foundation to January 2013. The studies were screened according to the inclusion and exclusion criteria and then the data were extracted. The methodological quality of included studies was assessed and meta-analysis was performed by Revman 5 software.
RESULTS AND CONCLUSION:This study final y included 15 randomized control ed trials, a total of 1 203 patients, including 616 in statins group and 587 in control group. The fixed and random effect models were used to analyze mini-mental state examination and activity of daily living scales including 14 scoring method and the Barthel index score. Compared with the control group, mini-mental state examination scores in the patients of statins group (14 randomized control trials, 1 112 patients) were, mean difference (MD)=3.02, 95%confidence interval (CI):2.26 to 3.77, P<0.000 1;activity of daily living scores (14 scoring method, 7 randomized control ed trials, 513 patients) were, MD=-4.14, 95%CI:-6.11 to-2.18, P<0.000 1;the Barthel index scores (2 randomized control ed trials, 171 patients) were, MD=11.62, 95%CI:9.78 to 13.46, P<0.001. Our study mentioned a total of 14 cases of adverse reactions. One case was in control group, and the other 13 cases were in statins group which were al caused by atorvastatin. There were no serious adverse reactions in statins group and the rate of adverse reactions was 2.1%. The current evidence suggested that statins can improve cognitive function in patients with vascular cognitive impairment, with good safety. However, further conclusion stil requests higher quality of randomized control ed trials.
